Immunotherapy as first treatment for advanced stage IV cancers
Part of Cancer clinical trials.
This study looks at whether immune checkpoint inhibitors given as the first treatment work well and are safe for people with advanced (stage IV) solid tumors. You might qualify if you can take study treatment reliably and your cancer type and health match the study rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the consent form and follow the study plan
- Your cancer is confirmed by biopsy/pathology (tissue diagnosis)
- Your cancer is stage IV (as defined for lung cancer in the IASLC staging system)
- You are 18 to 75 years old, and expected to live more than 3 months
- Your body is healthy enough for treatment (heart, liver, and kidneys not severely impaired)
- No major reason you cannot take immune checkpoint inhibitors (immunotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This study looks at how well immunotherapy drugs (like checkpoint inhibitors) work for different cancers. If you are already planning to receive this type of treatment, researchers want to track your outcomes and see how you do over time.
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This Phase 1/2 trial tests an immune-based treatment for advanced (Stage III–IV) GI cancer. You may be able to join only if your tumor shows certain “marker” proteins on special lab staining, and your blood and organ tests meet study limits.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.